15 results on '"Bosquet, L."'
Search Results
2. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
3. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort
4. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
5. 217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort
6. 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database
7. 1806P Clinical characteristics and management of small cell lung cancer long survivors
8. 774P Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database
9. 1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
10. 1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
11. 1402P Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
12. 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
13. 796P Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
14. 1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
15. 596P CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.